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Abstract
Background: Medulloblastoma is the most common malignant brain tumor in children. To date only few cases of
medulloblastoma with hemorrhages have been reported in the literature. Although some studies speculate on the
pathogenesis of this anomalous increased vascularization in medulloblastoma, the specific mechanism is still far
from clearly understood. A correlation between molecular medulloblastoma subgroups and hemorrhagic features
has not been reported, although recent preliminary studies described that WNT-subtype tumors display increased
vascularization and hemorrhaging.
Case presentation: Herein, we describe a child with a Wnt-medulloblastoma presenting as cerebellar-vermian
hemorrhagic lesion. Brain magnetic resonance imaging (MRI) showed the presence of a midline posterior fossa
mass with a cystic hemorrhagic component. The differential diagnosis based on imaging included cavernous
hemangioma, arteriovenous malformation and traumatic lesion. At surgery, the tumor appeared richly vascularized
as documented by the preoperative angiography.
Conclusions: The case we present showed that Wnt medulloblastoma may be associated with anomalous
vascularization. Further studies are needed to elucidate if there is a link between the hypervascularization and
the Wnt/β-catenin signaling activation and if this abnormal vasculature might influence drug penetration
contributing to good prognosis of this medulloblastoma subgroup.
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Background
Medulloblastoma is the most common malignant brain
tumor in children, representing approximately 25 % of
all pediatric brain tumors [1]. Current molecular stratifi-
cation consists in four subgroups associated with differ-
ent pathways defined as Wnt, Sonic Hedgehog Homolog
(SHH), group 3, and group 4 [2]. Wnt subtype is the rar-
est subgroup, accounting for 10 % of medulloblastomas
[3] and patients with this pathway activation have a very
good long-term prognosis [4]. However, the biological
effect of Wnt/β-catenin signaling activation and the link
with a better prognosis has not been clarified yet. Few
cases of medulloblastoma presenting with spontaneous
hemorrhage are reported in the literature [5]. Although
some studies speculate on the etiology of the anomalous
increased vascularization in medulloblastoma [6], a clear
pathogenetic role has not been identified. A correlation
between specific medulloblastoma subgroup and
hemorrhagic features has not been reported [7], however
a recent paper demonstrated that Wnt medulloblastoma
secretes Wnt antagonists that increase the permeability
of the blood–brain barrier (BBB) [8]. Furthermore, a per-
sonal communication hypothesized that this aberrant
vascular network may be associate with the Wnt sub-
group [9]. Herein, we report the case of a child with a
Wnt medulloblastoma presenting as a hemorrhagic
cerebellar-vermian lesion.
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Case presentation
A 7-year-old girl presented to the emergency depart-
ment of Bambino Gesù Children’s Hospital with a one-
month history of headache and vomiting. Neurological
examination was normal apart from mild dysmetria at
the upper extremities. Multidetector computed tomog-
raphy (MDCT) reconstruction images show a hyper-
dense cerebellar-vermian lesion, with fluid-blood levels.
This finding was confirmed by brain magnetic resonance
imaging (MRI) that showed the presence of a mass with
a hyperintense cystic hemorrhagic component, heteroge-
neous enhancement, poor perilesional edema and ab-
sence of obstructive hydrocephalus (Fig. 1A). Spinal MRI
and cerebrospinal fluid study were normal. Due to these
atypical features a cerebral angiography was performed,
showing an intratumoral aneurysm-like formation sup-
plied by a vermian branch of the left posterior inferior
cerebellar artery (Fig. 1A). She underwent a midline sub-
occipital craniotomy with complete resection of the
vermian tumor. At surgery, the tumor appeared richly
vascularized from vermian branches as documented by
the preoperative angiography. Histology (Fig. 1B)
showed a diffuse and multinodular proliferation of small
undifferentiated cells and immunohistochemistry re-
vealed positivity for synaptophysin and β-catenin (both
cytoplasmic and nuclear), all features consistent with the
diagnosis of classic medulloblastoma. The tumor was
characterized by anomalous vascularization and har-
bored some clusters of anomalous, thick-walled vascular
structures along with numerous variably anastomosing
small venous and capillary structures. Gene expression
profile of the tumor confirmed a Wnt molecular
subgroup (Fig. 2). C-Myc amplification was negative (C-
Myc/SPAST and C-Myc/PI4KA). She started therapy as
per standard arm of European HIT-SIOP PNET 4 trial
which is used for the treatment of standard risk medul-
loblastoma. According to this protocol, she received
radiotherapy (23 Gy to the craniospinal axis and a total
Fig. 1 MRI and histological findings in the hemorrhagic lesion. (A) [CT and MRI findings in the hemorrhagic cerebellar lesion]. Sagittal (a) and
Axial (b) MDCT reconstruction images show a hyperdense cerebellar-vermian lesion, with fluid-blood levels (white arrows), confirmed by MRI scan.
Axial T2-weighted MRI (c) showed a hemorrhagic cerebellar-vermian lesion, expanding into IV ventricle, with multiple fluid-blood levels (white arrow).
Axial-Sagittal T1-weighted MRI, without (d, e) and with (f, g) gadolinium, revealed a solid component inhomogeneously contrast-enhanced
(white arrows). Axial gradient-echo sequence (h) showed lack of hypointense hemosiderin rim (cavernous hemangioma classical finding,
white arrow). Preoperative left vertebral angiograms (i, l) show hypoplastic vertebral artery terminating as posterior inferior cerebellar artery
(vascular variation) and the tumor stain; an aneurysm-like formation (arrow) is seen in the arterial phase. The tumor is fed by the vermian branch of the
left posterior inferior cerebellar artery. (B) [Histological findings in hemorrhagic medulloblastoma]. Proliferation of small undifferentiated cells showing
a diffuse/multinodular pattern (middle-right), associated to anomalous, thick-walled vascular structures (arrows) (a, H&E, 2.5x). Cells were synaptophysin
(b, 20x) and beta-catenin (both cytoplasm and nucleus) positive (c, 20x). Anomalous vascularization was characterized by clusters of anomalous,
thick-walled arterial-type vessels (d and f, CD31 20x) along with numerous variably anastomosing small venous and capillary structures
(e, CD31, 20x)
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of 54 Gy to posterior fossa) given concurrently with
weekly vincristine (1.5 mg/m2 i.v.). This treatment was
followed by 8 cycles of maintenance-chemotherapy con-
sisting of cisplatin (70 mg/m2 i.v.) and lomustine (75 mg/
m2 orally) on day 1 associated to vincristine (1.5 mg/m2
i.v.) on day 1, 8 and 15. At 22 months after diagnosis she
was doing well with no evidence of disease.
The consensus held in Boston in 2010 supported the
existence of four main medulloblastoma subgroups
based on the molecular profiling and provided important
insights not only in the selection of patients for molecu-
lar targeted therapies but also in the outcome prediction
[2, 3, 10]. Medulloblastomas with activation of Wnt/β-
catenin pathway are rarely metastatic and appear to be a
less aggressive variant associated with an excellent prog-
nosis [11]. However, the significance of Wnt activation
in medulloblastoma remains to be determined. Several
findings suggest that wild type β-catenin has an import-
ant physiological role in CNS angiogenesis. During em-
bryogenesis, the Wnt pathway has direct actions on
axonal growth through interaction with β-catenin com-
plex [12]. Moreover, it has been demonstrated that Wnt
signaling plays an active role in the induction and main-
tenance of BBB characteristics during embryonic and
postnatal development particularly by regulating tight
junction proteins expression [13]. Indeed, Wnt/β-catenin
signaling is very important for central nervous system
(CNS) angiogenesis and conditionally inactivation of β-
catenin in the endothelium has been described to alter
the development of head vasculature resulting in early
embryonic lethality of mice [14, 15]. β-catenin–null ani-
mals show vessel fragility, in association to a decrease in
intercellular adhesion strength and an increase in
paracellular permeability leading to vascular leakage and
frequent hemorrhages. The critical role of canonical
Wnt signaling in endothelial cells for formation and dif-
ferentiation of the CNS vasculature has been described
also in genetic mouse models [16]. Recently has been re-
ported that G-protein coupled receptor 124 (GPR124)
functions as a specific co-stimulator of β-catenin signal-
ing in brain endothelium and its disruption led to de-
fective CNS angiogenesis and blood brain barriergenesis
in mice [17]. In mouse embryos, eliminating neuroepi-
thelial Wnt7a and Wnt7b, or endothelial Gpr124 or β-
catenin, leads to a reduced CNS angiogenesis with
formation of abnormal vascular structures [13, 16, 18]
and has been demonstrated that the interaction of
Gpr124 with Reck strongly synergize to promote Wnt/β-
catenin signaling during brain angiogenesis [19].
Nevertheless, most of the studies correlating Wnt sig-
naling with CNS vasculature anomalies are developmental
phenotypes, and the relevance to post-natal development
is not clear. Moreover, β-catenin is important in the regu-
lation of vascular endothelial cell-cell adhesions and bar-
rier function by linking the VE-cadherin junction complex
to the cytoskeleton and thus vascular anomalies may arise
for a non-signaling role [20].
A recent study showed that genetically modified
mouse models harboring Wnt-medulloblastoma had
more hemorrhagic tumors compared to SHH or group 3
tumors [8]. The authors demonstrated that these effects
occur postnatally and reveal that Wnt medulloblastoma
secretes Wnt antagonists increasing the permeability of
the BBB [8].
We report a girl with a Wnt medulloblastoma present-
ing an anomalous vascularization. Differential diagnosis
based on MRI imaging appearance includes cavernous
hemangioma, arteriovenous malformation and traumatic
lesion. Angiographic opacification of dilated arteriolar
vessels with slow flow and lack of early venous drainage
Fig. 2 Molecular characterization of medulloblastoma. mRNA levels of the indicated genes in medulloblastoma are compared to normal cerebellum
as control (CTRLs). Genes are grouped into four molecular subgroups (WNT, SHH, GROUP 3, GROUP 4) as indicated by the four different colors. Relative
quantification values are expressed as linear scale arbitrary units
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confirmed an aberrant tumor vascular network. This
patient is doing well at 22 months after diagnosis.
Medulloblastoma can present heterogeneous features
on MRI with variable enhancement patterns, cystic
areas, hemorrhage and calcification [21]. Although
intratumoral bleeding can be found in brain tumors,
only few cases of medulloblastoma with spontaneous
hemorrhages have been reported in the literature [5, 22].
Park et al. showed that the incidence of spontaneous
hemorrhage was 5.6 % in patients with primary or recur-
rent medulloblastoma [23]. A study evaluating vascular
regulatory expression profiles across medulloblastoma
subgroups documented an upregulation of proangiogenic
factors in SHH subgroup [6]. Despite specific mechanisms
driving aberrant vascularization and hemorrhage in me-
dulloblastoma remain not completely elucidated, new re-
searches revealed that medulloblastoma genotype dictates
tumor vessels phenotype [8].
Conclusions
We reported a case of Wnt/β-catenin medulloblastoma
associated with an anomalous vascularization. This may
support the evidence that Wnt medulloblastomas may
be associated to aberrant vascular network contributing
to a better drug penetration and therefore to their ex-
cellent prognosis [8]. This finding should be further
investigated in a large patient cohort in order to elucidate
the vascular microenvironment in Wnt medulloblastoma
subgroup.
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